Lipanthyl Nt (Fenofibrate (Nanonised))

Fenofibrate, the active ingredient in Lipanthyl Nt, is a fibrate presented as a tablet for oral use. It treats hypertriglyceridemia and related lipid disorders in adults.

GNH USA supplies Lipanthyl Nt as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate is used to modify lipid profiles in disorders characterized by elevated triglycerides and mixed dyslipidaemia.

- Hypertriglyceridemia: reduces markedly elevated triglyceride concentrations. - Mixed dyslipidaemia: improves overall lipid profile by lowering triglycerides and modestly raising HDL‑cholesterol. - Primary hypercholesterolaemia (as adjunct therapy): enhances LDL‑cholesterol reduction when combined with statins.

Fenofibrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia. - Headache. - Elevated liver enzymes. - Muscle pain or weakness. - Increased serum creatinine. - Skin rash.

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy. - Acute liver injury or hepatitis. - Pancreatitis. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome). - Renal impairment. - Hemorrhagic complications when combined with anticoagulants.

Before initiating therapy, clinicians should assess relevant clinical factors and monitor patients during treatment.

- Liver function: evaluate baseline hepatic enzymes and monitor periodically. - Renal function: assess creatinine clearance, especially in the elderly. - Gallstone disease: avoid in patients with active biliary disease. - Severe hypertriglyceridaemia (>1000 mg/dL): consider alternative or adjunctive therapy. - Concomitant statin use: monitor for signs of myopathy. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Fenofibrate can interact with several medicines, requiring avoidance or careful monitoring.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy. - Cyclosporine: raises fenofibrate plasma concentrations. - Warfarin: may potentiate anticoagulant effect. - HIV protease inhibitors: increase fenofibrate exposure. - High‑dose statins: elevate risk of rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., dabigatran): monitor coagulation parameters. - Thyroid hormones: adjust levothyroxine dose as needed. - Oral contraceptives: observe for lipid changes. - Niacin: increased potential for hepatotoxicity. - Digoxin: possible increase in serum levels.